Live
FierceBiotechEntry Japan with Clarity, Execute with ConfidenceEndpoints News#ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroupClinical OMICsPersonalized Cancer Vaccine Reduces Melanoma Recurrence by 49%FierceBiotechLilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclearEndpoints NewsLilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontEndpoints News#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainBioPharma Dive2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?FierceBiotechLilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndromeEndpoints NewsOculis’ eye drops for diabetic macular edema flunk Phase 3 testeLifeInterplay between cohesin and TORC1 links chromosome segregation and gene expression to environmental changeseLifeDistinct evolutionary trajectories of two integration centres, the central complex and mushroom bodies, across Heliconiini butterflieseLifeBeta-Glucan modulates monocyte plasticity and differentiation capacity to mitigate DSS-induced colitis
Thermo Fisher Feb 26, 2026

Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner - BioSpace

Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Soone...

Body unavailable. Use the original source.